How do you pay?

How to pay the least

Ask for the cash price

Opsynvi

We didn’t find one.

  1. Ask your pharmacy for Opsynvi’s cash price, and one or two other pharmacies too.
  2. Opsynvi’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program (pulmonary hypertension medicines). Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify 

Compare every option

Question
Brand nameOpsynvi
Authorized genericmacitentan and tadalafil
Regular genericmacitentan and tadalafil
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Opsynvi?
The original
–
–

Brand nameThe maker’s card

J&J withMe Oral PAH Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a fill

Sign up on jnjwithme.com 

Or call 1-833-742-0791.

In the maker’s words

“Eligible patients pay $5 per prescription fill.”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Opsynvi itself, from the same company, sold without the brand name, and usually for less. For now Opsynvi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II–III.

Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability.

Source: the FDA label for Opsynvi (Actelion Pharmaceuticals US, Inc.), April 11, 2025. Full label on DailyMed 

Good to know